Musings

Few thoughts on possible news flow, possible timing and hopefully commercialisation along the path.

Jul
End of SPP - This allows BIT market to return to normal demand.
Statement on SPP - Will $2.0 million be raised?
Quarterly - Should include r&d refund and placement money.

Aug
Annual report - Excellent progress to report on.

Sep
Bit225-008 - Genotype 3 results. May still be possible for 100% cure if the 4% (1 patient?) that didn't reach >2 log reduction was from the genotype1 stream?
Will there still be an increased rate of decline as in previous trials?

Oct
IND submission - Will we know the DAA and what impact will this have?
HIV trial planning update
MMiller options - Will BIT be in the money and allow conversion

2016 & beyond
Genotype1 results
R&D Refund
Option conversions
Dengue trials possible
Bit314 trials possible

Depending on required future expenditure and given optimum conditions hopefully will have sufficient funds with conversion of existing options to allow for a couple of years.
31 Mar 2015 2.2
30 Jun 2015 -1.1 R&D Refund, Placement. 3.7 4.8
30 Sep 2015 -1.8 SPP 2.0 5.0
31 Dec 2015 -1.8 MMiller Option conversion. 1.1 4.3
31 Mar 2016 -1.8 2.5
30 Jun 2016 -1.8 R&D Refund 1.7 2.4
30 Sep 2016 -1.8 Option conversion 6.0 6.6
31 Dec 2016 -1.8 4.8
31 Mar 2017 -1.8 3.0
30 Jun 2017 -1.8 R&D Refund 2.6 3.8
30 Sep 2015 -1.8 2.0


v